Propafenone in the Treatment of Atrial Fibrillation
Status:
Completed
Trial end date:
2021-08-17
Target enrollment:
Participant gender:
Summary
This is a open label randomized, multi-center study conducted in Taiwan. The study aims to
evaluate the effectiveness and safety of oral Rhynorm (A drug) and Rytmonorm (B drug) for the
conversion of paroxysmal AF and is designed to evaluate the improvement in sinus rhythm
restoration after the treatment with Rhynorm (A drug) and Rytmonorm (B drug) for 24 weeks.